X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
guselkumab (73) 73
psoriasis (53) 53
index medicus (36) 36
efficacy (28) 28
adalimumab (27) 27
safety (27) 27
ustekinumab (25) 25
dermatology (24) 24
humans (23) 23
tildrakizumab (21) 21
moderate (20) 20
double-blind (18) 18
il-23 (18) 18
phase-iii (18) 18
psoriasis - drug therapy (17) 17
secukinumab (17) 17
pharmacology & pharmacy (15) 15
plaque psoriasis (15) 15
risankizumab (15) 15
antibodies, monoclonal - therapeutic use (14) 14
biologics (13) 13
brodalumab (12) 12
ixekizumab (11) 11
monoclonal antibodies (11) 11
pathogenesis (11) 11
to-severe psoriasis (11) 11
cytokines (10) 10
il-17 (10) 10
interleukin 23 (10) 10
interleukin-23 (10) 10
clinical trials (9) 9
immunology (9) 9
inflammation (9) 9
monoclonal-antibody (9) 9
psoriasis - immunology (9) 9
anti-interleukin-23 monoclonal-antibody (8) 8
antibodies, monoclonal - adverse effects (8) 8
etanercept (8) 8
interleukin-12/23 monoclonal-antibody (8) 8
interleukin-23 - antagonists & inhibitors (8) 8
severe plaque psoriasis (8) 8
voyage 1 (8) 8
apremilast (7) 7
dermatologic agents - adverse effects (7) 7
dermatologic agents - therapeutic use (7) 7
interleukins (7) 7
mirikizumab (7) 7
placebo (7) 7
trial (7) 7
animals (6) 6
arthritis (6) 6
brazikumab (6) 6
controlled-trial (6) 6
infliximab (6) 6
interleukin 17 (6) 6
patients (6) 6
review (6) 6
severity of illness index (6) 6
skin (6) 6
treatment outcome (6) 6
voyage 2 (6) 6
interleukin-23 - immunology (5) 5
interleukin-23 subunit p19 - antagonists & inhibitors (5) 5
maintenance therapy (5) 5
male (5) 5
middle aged (5) 5
population (5) 5
quality of life (5) 5
studies (5) 5
therapy (5) 5
adult (4) 4
biologic (4) 4
care and treatment (4) 4
crohn's disease (4) 4
crohn’s disease (4) 4
double-blind method (4) 4
female (4) 4
il-23/il-17 axis (4) 4
inflammatory bowel disease (4) 4
interleukin-17 (4) 4
placebos (4) 4
pooled analysis (4) 4
psoriasis - diagnosis (4) 4
psoriasis - pathology (4) 4
abridged index medicus (3) 3
adalimumab - therapeutic use (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal - pharmacokinetics (3) 3
association (3) 3
biotechnology & applied microbiology (3) 3
chronic plaque psoriasis (3) 3
clinical trials as topic (3) 3
collagen-induced arthritis (3) 3
dendritic cells (3) 3
disease (3) 3
eczema (3) 3
ifn-gamma (3) 3
il-23 inhibitor (3) 3
il-23p19 (3) 3
il23 (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Dermatology Online Journal, ISSN 1087-2108, 01/2019, Volume 25, Issue 1
Development of lentigines in areas of resolving psoriatic plaques is a rare phenomenon that has been reported following various treatment modalities including... 
Psoriasis | Lentigines | Guselkumab
Journal Article
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, ISSN 0190-9622, 03/2017, Volume 76, Issue 3, pp. 418 - 431
Background: Phase II data suggested that guselkumab, an anti-interleukin-23 monoclonal antibody, was efficacious in psoriasis. Objective: We sought to assess... 
switching | POPULATION | USTEKINUMAB | guselkumab | adalimumab | efficacy | interleukin-23 | DERMATOLOGY | THERAPY | VOYAGE 2 | VOYAGE 1 | TREATMENT PATTERNS | psoriasis | safety | PLAQUE PSORIASIS | ETANERCEPT
Journal Article
The Journal of Allergy and Clinical Immunology, ISSN 0091-6749, 09/2017, Volume 140, Issue 3, pp. 645 - 653
Journal Article
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, ISSN 0190-9622, 03/2017, Volume 76, Issue 3, pp. 405 - 417
Background: Guselkumab, an interleukin-23 blocker, was superior to adalimumab in treating moderate to severe psoriasis in a phase II trial. Objectives: We... 
TO-SEVERE PSORIASIS | scalp psoriasis | USTEKINUMAB | INTERLEUKIN-23 | CYTOKINE | INNATE LYMPHOID-CELLS | guselkumab | adalimumab | efficacy | hand and foot psoriasis | DERMATOLOGY | THERAPY | nail psoriasis | VOYAGE 2 | VOYAGE 1 | psoriasis | safety | SEVERE PLAQUE PSORIASIS | QUALITY-OF-LIFE | LONG-TERM EFFICACY
Journal Article
Expert Opinion on Biological Therapy, ISSN 1471-2598, 02/2019, Volume 19, Issue 2, pp. 89 - 98
Journal Article
by Ring, J
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 01/2019, Volume 33, Issue 1, pp. 7 - 10
Journal Article
Expert Opinion on Investigational Drugs, ISSN 1354-3784, 08/2018, Volume 27, Issue 8, pp. 649 - 660
Journal Article
Journal Article
JAAD Case Reports, ISSN 2352-5126, 11/2019, Volume 5, Issue 11, pp. 973 - 975
Journal Article
Journal Article
Chinese Journal of New Drugs, ISSN 1003-3734, 04/2018, Volume 27, Issue 8, pp. 899 - 904
Journal Article
Nature Reviews Rheumatology, ISSN 1759-4790, 07/2015, Volume 11, Issue 7, pp. 415 - 429
Journal Article
Australian prescriber, ISSN 0312-8008, 06/2019, Volume 42, Issue 3, pp. 105 - 106
Journal Article
Dermatologic Therapy, ISSN 1396-0296, 07/2019, Volume 32, Issue 4, pp. e12954 - n/a
A 40‐year‐old man with chronic history of refractory palmoplantar psoriasis presented with new onset of well‐demarcated oval erythematous asteatotic plaques on... 
dermatitis | psoriasis | IL23 | guselkumab | Th17 | palmoplantar | nummular | PUSTULOSIS | ECZEMA | DERMATOLOGY | Skin | Inflammation | Psoriasis | Dermatitis
Journal Article
The Journal of Dermatology, ISSN 0385-2407, 12/2019, Volume 46, Issue 12, pp. 1141 - 1152
Guselkumab, an interleukin‐23 blocker, was superior to placebo and adalimumab and well‐tolerated in phase 3 psoriasis studies (VOYAGE 1 and VOYAGE 2). This... 
South Korea | guselkumab | interleukin‐23 monoclonal antibody | psoriasis | Taiwan
Journal Article
BRITISH JOURNAL OF DERMATOLOGY, ISSN 0007-0963, 01/2018, Volume 178, Issue 1, pp. 22 - 22
Journal Article
Journal of Dermatological Treatment, ISSN 0954-6634, 05/2019, Volume 30, Issue 4, pp. 374 - 375
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2014, Volume 133, Issue 4, pp. 1032 - 1040
Journal Article
Journal of Medical Economics, ISSN 1369-6998, 12/2019, Volume 22, Issue 12, pp. 1268 - 1273
Aims: To estimate annual cost per response (CPR) in the US and number needed to treat (NNT) among patients receiving guselkumab or adalimumab treatment for... 
cost-effectiveness | CPR | NNT | psoriasis | Cost per responder | number needed to treat | guselkumab | adalimumab
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.